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Abstract
Background: This study aimed to investigate risk factors for colonisation with extensively drug-resistant P. aeruginosa
(XDR-PA) in immunocompromised patients and to build a clinical risk score (CRS) based on these results.
Methods: We conducted a matched case–control study with 31 cases and 93 controls (1:3). Cases were colonised with
XDR-PA during hospitalisation. Independent risk factors were determined using a three step conditional logistic regression
procedure. A CRS was built with respect to the corresponding risk fraction of each risk factor, and its discriminatory power
was estimated by receiver operating characteristic (ROC) analysis.
Results: The presence of a central venous catheter (OR 7.41, P = 0.0008), the presence of a urinary catheter (OR 21.04, P <
0.0001), CRP > 10 mg/dl (OR 7.36, P = 0.0015), and ciprofloxacin administration (OR 5.53, P = 0.025) were independent risk
factors. The CRS exhibited a high discriminatory power, defining a high risk population with an approximately fourteen
times greater risk for XDR-PA colonisation.
Conclusions: Unnecessary use of antibiotics, particularly ciprofloxacin should be avoided, and a high standard of infection
control measures must be achieved when using medical devices. A CRS can be used for adaptation of the active
screening culture policy to the local setting.
Keywords: XDR, Predictors of colonisation, IMP carbapenemase, VIM carbapenemase, Clinical risk score, Clinical score
construction, Matched case–control study, Conditional logistic regression
Background
The opportunistic human pathogen Pseudomonas aerugi-
nosa is among the most common bacteria in health-care as-
sociated infections in Europe [1]. Severe invasive disease,
particularly with multidrug-resistant strains, involves high
mortality rates [2,3]. Early detection of carriers in high-risk
patients is a crucial requirement to reduce spread of
resistant strains and to administer appropriate empirical
treatment in case the pathogen becomes invasive. On that
account there is an essential need for a comprehensive
knowledge of risk factors for nosocomial colonisation with
resistant P. aeruginosa.
Prior exposures to antimicrobials or medical devices
are common risk factors reported [4-6] but these studies
are heterogeneous in terms of design, patient population
and definition of multidrug resistance. The latter issue is
likely to be improved due to the publication of an inter-
national expert proposal that defined bacterial resist-
ance profiles on the basis of epidemiological relevant
antimicrobial categories [7]. The extensively drug-resistant
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P. aeruginosa (XDR-PA) that remains susceptible to a
maximum of two classes of antimicrobials is clinically
highly relevant due to the limited treatment options, its
frequent isolation from ICU patients [8] and the recently
observed international spread [9]. Risk factors have been
primarily determined for invasive disease with XDR-PA
[10-12] but predictors of patient colonisation have not yet
been described.
In this study, we investigated potential risk factors for
nosocomial XDR-PA colonisation in a haematological pa-
tient population. Consecutively, these results were used to
construct a clinical risk score for the identification of pa-
tients at high risk for nosocomial XDR-PA colonisation,
and the relative merit of this score as tool for efficient
structuring of a local active screening culture policy in an
endemic setting with XDR-PA was discussed.
Methods
Setting
The study was performed on the wards of the Department
of Haematology in a 1500-bed tertiary teaching hospital in
Tübingen, Germany. There are 80 beds at the depart-
ment for the treatment of patients having various
haematological-oncological conditions, such as leukae-
mia, lymphoma and multiple myeloma. Stem cell trans-
plantations are regularly performed. One ward is an
intensive care unit with single rooms. Routine screening
for P. aeruginosa was carried out at admission and weekly
thereafter. The screening involved rectal and pharyngeal
swabs. Other diagnostic cultures were performed accord-
ing to clinical status. The study is reported in conformity
with the STrengthening the Reporting of OBservational
studies in Epidemiology (STROBE) guidelines [13]. The
study has been approved by the local research ethics com-
mittee of the University of Tübingen (reference number:
659/2012R).
Study design, patients and definitions
This matched case–control study was conducted from
January 2010 to December 2013. Adult patients (≥
18 years) hospitalised > 48 h were considered eligible.
Designation as case patient was based on the acquisition
of a new hospital-acquired colonisation with an exten-
sively drug-resistant P. aeruginosa (XDR-PA). XDR-PA
were considered as hospital-acquired if they were diag-
nosed >48 h after admission. XDR-PA was defined ac-
cording to the CDC/ECDC criteria [7]. The following
antimicrobials were tested at our center: gentamicin, tobra-
mycin, amikacin, piperacillin, piperacillin-tazobactam, cef-
tazidime, cefepime, ciprofloxacin, levofloxacin, meropenem,
aztreonam, fosfomycin, and colistin. Intermediately suscep-
tible isolates were considered resistant. The control group
was composed of patients with either negative screening
cultures for P. aeruginosa or of patients from whom a Non-
XDR-P. aeruginosa was isolated. Controls were matched to
cases for calendar time (quarters) and ward, and three con-
trols were recruited for each case.
Time at risk was defined as time span between admis-
sion and new colonization with XDR-PA for cases, and
as time span between admission and the last XDR-PA
negative screening culture during hospitalisation for
controls. According to the criteria mentioned above the
minimum time at risk was three days. The primary ex-
posure of interest was administration of antimicrobial
agents. Furthermore, the length of administration (in
antibiotic-days) was recorded as well as the total dose,
converted into defined daily doses (DDD) conformable
to the 2014 World Health Organization (WHO) ana-
tomical therapeutic chemical (ATC) classification sys-
tem [14]. Investigated antibiotics were given per os and/or
intravenously and included cephalosporins (cefuroxime,
ceftazidime and cefepime), quinolones (levofloxacin and
ciprofloxacin), meropenem, piperacillin-tazobactam, amino-
glycosides (gentamicin, tobramycin and amikacin), cotri-
moxazole, macrolides (erythromycin, clarithromycin and
azithromycin), doxycycline, metronidazole, vancomycin,
rifampicin, clindamycin, flucloxacillin, and aztreonam.
Patient files were reviewed by medically trained staff.
Clinical data included time at risk; antibiotic treatment;
age; sex; length of ICU stay, infectious diseases not caused
by P. aeruginosa (IDNPA); baseline diseases; immunosup-
pression, such as neutropenia (< 1000 cells/μl) and/or
HIV and/or immunosuppressive chemotherapy within the
previous two month (anti-inflammatory monoclonal anti-
body and anti-cancer drugs) and/or receipt of steroids
(prednisolon ≥ 10 mg/daily or equivalent dose); Charlson
comorbidity score at admission [15]; simplified acute
physiology score II (SAPS II) at admission (+ 48 h) [16];
exposure to medical devices; baseline laboratory parame-
ters during time at risk; and prior room occupation by a
case patient (within 30 days and 6 weeks).
Laboratory-based testing
Material from rectal and pharyngeal swabs was inoculated
on cetrimide agar (Cetrimide Agar Base 285420, Becton,
Dickinson and Company, Heidelberg, Germany). Species
identification was performed by a linear MALDI-TOF
mass spectrometer (AXIMA Assurance, bioMérieux,
Marcy l’Etoile, France), supplemented by Vitek 2 system
identification (bioMérieux, Marcy l’Etoile, France). Anti-
microbial susceptibility testing was carried out with the
Vitek 2 system (bioMérieux, Marcy l’Etoile, France) and
interpreted following EUCAST guidelines [17].
The simultaneous detection of blaVIM and blaIMP genes
was performed with a multiplex PCR according to a
protocol described elsewhere [18]. The VIM and IMP
genes were entirely sequenced using the primer pairs
IMP-A–IMP-B or VIM2004A-VIM2004B in combination
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with the class 1 integron primer pair 5CS and 3CS or alter-
natively VIM-2SQR [18,19]. Multilocus sequence typing
(MLST) was conducted according to the instructions on
the P. aeruginosa website (http://pubmlst.org/paeruginosa/).
Statistical analysis
D’Agostino’s K-squared test was employed to check con-
tinuous variables for normality. For skewed data, me-
dians and interquartile ranges (IQR) were provided.
However, median values and IQR were 0 for several con-
tinuous variables due to their skewed distribution. In such
a case, the mean and range were presented. The chi-
squared test or – when appropriate – the Fisher’s exact
test were performed to compare differences in proportion.
Odds ratios for XDR-PA colonisation were calculated
for all variables with a minimum exposure of n = 10.
Conditional logistic regression was used to calculate
crude odds ratios for patient-related clinical variables.
Any patient-related variable with a P-value of < 0.1 in
the univariate analysis was included in the Step I multi-
variate conditional logistic regression model and
retained when the P-value was < 0.05 using a backward
stepwise elimination procedure. A Step II model was
built by adding treatment-related variables (antibiotic
use, length, total dose) one at a time to the final Step I
model using conditional logistic regression. Length of
administration and total dose of an antibiotic were
investigated as quantitative variables to ensure that time-
or dose-dependent effects are not missed. Treatment-
related variables with a P-value < 0.1 in the Step II
model were subsequently added to the patient-related
variables from the Step I model, forming a final Step III
multivariate conditional logistic regression model. Vari-
ables were retained when the P-value was < 0.05 using a
backward stepwise elimination procedure as for the Step I
model. The final Step III model contained patient- and
treatment-related variables that were independent risk fac-
tors for an XDR-PA colonisation. Antibiotic use, length
of use and total dose were investigated in separate Step
III models to prevent biased results due to collinearity.
Potential interactions were investigated using the likeli-
hood ratio test.
For the construction of the clinical risk score (CRS)
we have added up the adjusted odds ratios of all inde-
pendent risk factors from the final Step III model and
calculated the risk fraction according to their proportion
of the total risk. Score points were allocated to each risk
factor as per risk fraction value. The CRS is comprised
of a total of 100 points. The discriminatory power of the
CRS as well as a suitable cutoff to distinguish between
patients with a high and low risk of being colonised with
an XDR-PA was estimated by a receiver-operating char-
acteristic (ROC) analysis.
A P-value < 0.05 (two-sided) was deemed statistically
significant. All analyses were carried out by using Stata
version 12.0 (Stat Corp., College Station, TX, USA).
Results
A total of 124 patients (31 cases and 93 controls) were
included in the risk factor analysis. Twenty-three case
patients (74.2%) developed a rectal and eight case pa-
tients (25.8%) a pharyngeal XDR-PA colonisation. All
XDR-PA strains were non-susceptible to piperacillin-
tazobactam, ceftazidime, ciprofloxacin, meropenem, and
aztreonam. Five XDR-PA (16.1%) were susceptible to ami-
noglycosides. A subset of 14 XDR-PA strains with identi-
cal susceptibility pattern was molecularly characterized.
Twelve strains carried an IMP-8 gene and belonged to
MSLT type 308 while two strains belonged to the MLST
type 233 and haboured a VIM-2 gene, indicating the pres-
ence of at least two endemic strains in our setting. Sixteen
control patients (17.2%) were colonised with a Non-XDR-
PA during their hospital stay. The remaining 77 control
patients (82.8%) were not colonized with P. aeruginosa.
In-hospital mortality was 12.9% (4/31) for cases compared
to 2.2% (2/93) for the controls (P = 0.016).
Baseline characteristics and crude odds ratios are pre-
sented in Table 1. While a number of patient-related vari-
ables seemed to increase the risk for XDR-PA colonisation,
only three variables turned out to be independent risk fac-
tors in the Step I multivariate model: presence of a central
venous catheter, presence of an urinary catheter, and CRP
during time at risk > 10 mg/dl (Additional file 1: Table S1).
Subsequently, the effect of treatment-related variables was
investigated. Generally, case patients were more likely to
have received antibiotics compared to controls (100% vs.
78.5%, P = 0.003). To gain more specific results, all
treatment-related variables were added to the Step I model
one at a time (Step II models). The administration of cipro-
floxacin and ceftazidime as well as the administration of
more than three different antibiotics during the time at risk
were associated with the risk of XDR-PA colonisation in
these Step II models (Table 1). However, only the consump-
tion of ciprofloxacin appeared to be an independent risk
factor in the final Step III model (Table 2). Of note, an in-
crease of risk with a higher total dose or a longer adminis-
tration of ciprofloxacin was not observed. The full list with
results of treatment-related variables from all Step II
models and the findings from all Step III models are shown
in the Additional file 1: Table S2 and S3, respectively.
The four independent risk factors were used to build a
clinical risk score. The CRS consists of 100 points, and
points were allocated according to the risk fraction of
each factor (Table 3). The presence of a urinary catheter
was given slightly lower points than indicated by round-
ing the risk fraction due to the large 95% confidence
interval in the final Step III model. The discriminatory
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power of the CRS was assessed by a ROC analysis. The
area under the ROC curve (AUC) was 0.83 (95% confi-
dence interval: 0.75 – 0.91). A cutoff was chosen to dif-
ferentiate the patients in those with a higher risk of
XDR-PA colonisation (high risk group) and those with a
lower risk (low risk group). Patients with a CRS ≥ 36
points have an odds of XDR-PA colonisation of 1.29,
thus associated with the high risk group. On the other
hand, patients with a CRS < 36 points have an odds of
XDR-PA colonisation of only 0.12 and thus belong with
Table 1 Baseline characteristics, comorbidities, laboratory and Step II treatment parameters of 124 patients: odds ratios
for risk of XDR-PA colonisation
Parameter Cases (n = 31) Controls (n = 93) Crude OR (95% CI) P-value
Basic parameters
Age, median (IQR), years 56 (48–68) 60 (51–70) 0.9835 (0.9539 - 1.0141)‡ 0.28
Female sex, % 11 (35.5%) 20 (21.5%) 1.19 (0.53 - 2.65) 0.68
Admission from home, % 26 (83.9%) 83 (89.3%) 0.61 (0.18 - 2.01) 0.42
Stay on ICU, % 12 (38.7%) 25 (26.9%) 6.23 (1.16 - 33.4) 0.024
Length of ICU stay, mean (range), days 10.58 (0–71) 9.66 (0–80) 1.0055 (0.9747 - 1.0374)‡ 0.73
Time at risk > 14 days, % 19 (61.3%) 39 (41.9%) 2.54 (1.01 - 6.34) 0.04
IDNPA, % 17 (54.8%) 20 (21.5%) 5.47 (1.95 - 15.37) 0.0004
Comorbid conditions
Immune suppression, % 30 (96.8%) 79 (85%) 5.35 (0.67 - 42.5) 0.05
Charlson Comorbidity Score, median (IQR) 2 (2–4) 2 (2–4) 1.13 (0.91 - 1.41) 0.28
Diabetes, % 5 (16.1%) 16 (17.2%) 0.92 (0.3 - 2.8) 0.89
Cardiovascular disease, % 15 (48.4%) 37 (39.8%) 1.44 (0.62 - 3.3) 0.4
Patient’s clinical record
SAPS II, mean (range) 27.97 (13–44) 26.32 (6–51) 1.0234 (0.9752 - 1.074)‡ 0.35
Neutropenia (<1000 cells/μl), % 22 (71%) 51 (54.8%) 2.13 (0.86 - 5.31) 0.095
Length of Neutropenia, median (IQR), days 9 (0–18) 2 (0–16) 1.0239 (0.9897 - 1.0592)‡ 0.17
Non-invasive ventilation, % 9 (29%) 24 (25.8%) 1.2 (0.46 - 3.13) 0.71
CVC, % 21 (67.7%) 40 (43%) 3.48 (1.35 - 9) 0.008
Length of CVC, mean (range), days 14.13 (0–59) 11.13 (0–86) 1.0155 (0.9867 - 1.0452)‡ 0.3
Urinary catheter, % 13 (41.9%) 8 (8.6%) 6.75 (2.38 - 19.17) 0.0001
Length of urinary catheter, mean (range), days 4.03 (0–20) 0.98 (0–23) 1.1159 (1.0266 - 1.2129)‡ 0.005
Room preoccupied by case (30 days), % 4 (12.9%) 7 (7.5%) 1.46 (0.48 - 8.4) 0.35
Room preoccupied by case (6 weeks), % 4 (12.9%) 9 (9.7%) 1.41 (0.38 - 5.22) 0.61
Most pathological laboratory
parameter during time at risk
White blood cell count, median (IQR), cells/μl 1260 (330–3170) 2060 (360–5720) 0.99998 (0.99993 - 1.00004)‡ 0.73
Neutrophils, median (IQR), cells/μl 320 (20–1076) 1090 (50–3383) 0.9999 (0.9998 - 1)‡ 0.14
Platelet count < 50,000 cells/μl, % 21 (67.7%) 44 (47.3%) 2.55 (1.04 - 6.28) 0.04
Creatinine, median (IQR), mg/dl 1.1 (0.8 - 1.4) 1 (0.8 - 1.2) 1.27 (0.85 - 1.88)‡ 0.24
CRP > 10 mg/dl, % 21 (67.7%) 32 (34.4%) 5.29 (1.88 - 14.89) 0.0005
Step II treatment variables* Cases (n = 31) Controls (n = 93) OR (95% CI) P-value
Ceftazidime use, % 10 (32.3%) 5 (5.4%) 4.28 (0.74 - 24.77) 0.09
Ciprofloxacin use, % 8 (25.8%) 11 (11.8%) 5.53 (1.11 - 27.53) 0.025
NDA > 3, % 20 (64.5%) 27 (29%) 4.35 (0.87 - 21.68) 0.06
‡Per 1 unit increase.
*All antibiotics with a P < 0.1 in the Step II models are listed.
XDR-PA, extensively drug-resistant Pseudomonas aeruginosa; IQR, interquartile range; ICU, intensive care unit; IDNPA, infectious diseases not caused by Pseudomonas
aeruginosa; SAPS II, Simplified Acute Physiology Score II; CVC, central venous catheter; CRP, C-reactive protein; DDD, defined daily dose; NDA, number of different
antibiotics during time at risk; 95% CI, 95% confidence interval.
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the low risk group. The risk of being a case is approxi-
mately fourteen times greater in the high risk group
(conditional logistic regression, OR 14; 95% confidence
interval: 4.1 – 47.9; P < 0.0001).
Discussion
Our study aimed to investigate potential risk factors of
XDR-PA colonisation in a haematological patient popu-
lation and to set up a clinical risk score to differentiate
between patients with a higher and lower risk of XDR-
PA acquisition.
The primary exposure of interest was the administration
of antimicrobial agents as this is one of the major concerns
for the acquisition of resistant strains. We found the use of
ciprofloxacin to be an independent risk factor. Ciprofloxa-
cin is used in our institution for prophylaxis in neutropenic
patients. The total dose and time span of administration
did not play a role. These results are in line with previous
reports for multidrug-resistant P. aeruginosa (MDR-PA)
acquisition in different settings [5,20,21]. In contrast, cef-
tazidime administration was not independently associated
with XDR-PA colonisation despite a tendency of being a
risk factor in the corresponding Step II model (OR 4.28,
P = 0.09). The hospital-wide use of cephalosporins was pre-
viously correlated with the incidence of XDR-PA in a
multivariate time series analysis and is thus likely to exist
for the hospital setting rather than for the Department of
Haematology alone [22]. However, an independent associ-
ation between ceftazidime administration and XDR-PA
colonisation in our haematological patient population can-
not be excluded due to limitations in the study power of
the present investigation. Moreover, the inclusion of pa-
tients with Non-XDR-PA colonisation into the control
group might have led to a selection bias according to Har-
ris et al. [23,24]. In the present study, this should have
caused only a minor bias if at all due to the low proportion
of these patients among the control group (17.2%). Regard-
ing these patients as a part of the source population from
which case patients could arise prevents a general selection
bias and retains the internal and external validity of our
study [25].
Another interesting discovery was an increase in risk
when more than three different antibiotics were adminis-
tered during hospitalisation (OR 4.35, P = 0.06). Although
this result was not confirmed in the final Step III model
and must thus be interpreted with caution, it suggests that
the use of different antibiotics could ease an at least tem-
porary establishment of XDR-PA, possibly due to a broader
and more destructive impact on the gut or respiratory tract
flora compared to treatment with fewer agents.
Surprisingly, a relatively low risk fraction for ciproflox-
acin use (13.4%) was observed when compared with in-
dependent patient-related risk factors. Primarily the use
of medical devices had a major impact on the risk of
XDR-PA colonisation (central venous catheter and urin-
ary catheter; joint risk fraction 68.8%, Table 3). A recent
meta-analysis has shown that medical devices are leading
risk factors for the acquisition of carbapenem-resistant
P. aeruginosa [6]. This indicates that invasive procedures
like insertion of catheters by medical personnel can con-
tribute to the spread and sustainment of resistance in
the hospital. Interestingly, in contrast to a previous re-
port we have not seen that prior occupation of a room
with a case patient has increased the risk for subsequent
patients [26]. This supports the hypothesis that medical
personnel represent – in terms of XDR-PA acquisition -
a greater risk for the patient than environmental contamin-
ation. However, the results of the univariate analysis suggest
that with every urinary catheter day evolves a stepwise in-
crease in the odds ratio for XDR-PA colonisation of ap-
proximately 11% (P = 0.005), indicating that having a
urinary catheter could lead to a patient behaviour, special
care or exposure to unknown environmental factors that
further increase the acquisition risk.
A C-reactive protein > 10 mg/dl was identified as an-
other independent and patient-related risk factor. It is
Table 2 Multivariate analysis (Step III): Odds ratios for
risk of XDR-PA colonisation
Variable OR (95% CI) P-value
Clinical parameters*
Central venous catheter 7.41 (1.98 - 27.68) 0.0008
Urinary catheter 21.04 (3.67 - 120.57) <0.0001
CRP > 10 mg/dl 7.36 (1.81 - 29.85) 0.0015
Treatment parameters – drug
Ciprofloxacin use 5.53 (1.11 - 27.53) 0.025
Ceftazidime use 1.9 (0.22 - 16.43) 0.56
NDA > 3 2.22 (0.36 - 13.65) 0.39
Treatment parameters – length of treatment
Ciprofloxacin, antibiotic-days 1.01 (0.88 - 1.16)‡ 0.88
Treatment parameters – total dosage
Ciprofloxacin total dose, DDD 1.01 (0.87 - 1.17)‡ 0.91
*The results shown are based on the final model with the treatment-related
variables for use of antibiotics.
‡Per 1 unit increase.
XDR-PA, extensively drug-resistant Pseudomonas aeruginosa; CRP, C-reactive
protein; NDA, number of different antibiotics during time at risk; DDD, defined
daily dose; 95% CI, 95% confidence interval.
Table 3 Buildup and structure of the clinical risk score
Score variable OR (step III) Risk fraction (%) Points
Central venous catheter 7.41 17.9% 18
Urinary catheter 21.04 50.9% 50
CRP > 10 md/dl 7.36 17.8% 18
Ciprofloxacin use 5.53 13.4% 14
XDR-PA, extensively drug-resistant Pseudomonas aeruginosa; CRP, C-reactive protein.
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not within the scope of our study to give a comprehen-
sive explanation for this finding, but it can be speculated
whether this reflects a pro-inflammatory situation or a
concomitant infectious disease that impairs the protect-
ive mucosal barrier and could thus promote a more ef-
fective adherence of the pathogen.
We have found a significantly higher in-hospital mor-
tality among case patients compared to controls (12.9%
versus 2.2%, P = 0.016). But this results need to be inter-
preted with caution since we have not directly investi-
gated the impact of XDR-PA colonisation on mortality.
However, it strengthens the findings of a previous study
in our setting where mortality was significantly different
between patients with bloodstream infection due to
metallo-β-lactamase (MBL) producing P. aeruginosa or
Non-MBL producing P. aeruginosa ( 61% versus 34%)
[27]. Additionally, Tacconelli et al. have reported that 9%
of patients with a new hospital-acquired colonisation
with an antibiotic resistant bacterium developed subse-
quently an infection due to the same pathogen [4]. Thus,
identifying the patients’ carrier status could improve
chances to choose an appropriate empirical treatment
when necessary, particularly in an institution with a rele-
vant incidence of multidrug-resistant pathogens.
The weekly rectal and pharyngeal screening for P. aer-
uginosa was introduced in our Department of Haematol-
ogy in response to an increase in the incidence of MDR-
and XDR-PA. It is a reasonable assumption that active
screening cultures (ASC) facilitate an early detection of
carrier status that should be followed by appropriate in-
fection control measures when an MDR- or XDR-PA is
found. On the other hand, there is no evidence at the
moment that ASC is effective in decreasing the inci-
dence of targeted organisms in the long-term, and thus
it is only recommended as an additional procedure [28].
However, ASC might be more effective if the screening
strategy is adapted to the local setting. The differenti-
ation into low and high risk groups according to local
risk factors and a subsequent modification of the screen-
ing frequency for both groups could be an approach to
efficiently allocate resources and focus on the patients
who could benefit the most from ASC. Our CRS exhibits
a high discriminatory power (AUC = 0.83) with an ap-
proximately fourteen times greater risk for nosocomial
colonisation with XDR-PA in the high risk group. An ex-
ample of how a weekly screening strategy for all patients
can be adjusted to the local setting by using such a CRS
is shown in Figure 1.
We are aware that our study has several limitations.
The CRS is derived from the odds ratios of significant
risk factors in our study population. Its true perform-
ance would need to be evaluated on another patient co-
hort in the same setting, preferably with a prospective
design. In addition, the study power could have been too
low to reveal moderately associated risk factors. Also,
this is a single center study and results are usually not
transferable to other settings. However, it must be stated
that even results of multicenter studies as well as recom-
mendations from generally accepted guidelines can turn
out as inappropriate. An example are the results from a
research group in eastern China who found the Ameri-
can Thoracic Society (AST) guidelines criteria not reliable
for the prediction of multidrug-resistant organisms in
their hospital [29]. For this reason, we recommend for any
setting i) to identify the locally most common resistant
pathogens, ii) to investigate the most relevant risk factors
for acquisition, and iii) to adapt the local infection control
policy according to the observed risk factors, for instance
in the context of a local CRS as suggested by our work.
Conclusion
We found ciprofloxacin use as well as patient-related
factors to independently increase the risk for XDR-PA col-
onisation. The results indicate that unnecessary administra-
tion of antibiotics, specifically ciprofloxacin should be
avoided and that a high infection control standard must be
accomplished when medical devices are used. Addition-
ally, a switch to alternative regimes for prophylaxis in
neutropenic patients is a recommendable option. Iden-
tified risk factors can be applied to adapt local screening
strategies for an early detection of resistant organisms
with a subsequently more efficient prevention of their
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Figure 1 Flow chart for a locally adapted active screening
culture (ASC) strategy. Patients once classified as high risk patients
for XDR-PA colonisation remain their status until discharge und are
screened twice a week.
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Additional file
Additional file 1: Additional tables including details from the
uni- and multivariate analysis which are not shown in the
manuscript text.
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